Multiple Sclerosis NewsJuly 13, 20263 minute read People living with multiple sclerosis could one day have another treatment option if a new biosimilar to Ocrevus receives regulatory approval. Teva Pharmaceuticals has reached an agreement with Polpharma Biologics to bring a proposed biosimilar version of Ocrevus (ocrelizumab) to markets around the world. The medication is still…